A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density
Abstract Background Perimenopausal women can experience rapid bone loss at skeletal sites with both cortical and cancellous bone, increasing the prevalence of osteoporosis following menopause. Methods We conducted a 12-month randomized placebo-controlled trial evaluating the effects of alendronate 7...
Gespeichert in:
| Veröffentlicht in: | Journal of obstetrics and gynaecology Canada 2014-11, Vol.36 (11), p.976-982 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 982 |
|---|---|
| container_issue | 11 |
| container_start_page | 976 |
| container_title | Journal of obstetrics and gynaecology Canada |
| container_volume | 36 |
| creator | Khan, Aliya, MD, FRCPC, FACP, FACE Dubois, Sacha, MPH Khan, Amina A Zohair Rahman, M., BSc Ahmed Khan, O., MD Syed, Hamid T Derzko, Christine, MD, FRCSC |
| description | Abstract Background Perimenopausal women can experience rapid bone loss at skeletal sites with both cortical and cancellous bone, increasing the prevalence of osteoporosis following menopause. Methods We conducted a 12-month randomized placebo-controlled trial evaluating the effects of alendronate 70 mg with 2800 IU cholecalciferol administered once per week for 12 months in comparison with placebo and cholecalciferol. The primary end-point was the percentage change in the lumbar spine bone mineral density (BMD) from baseline to 12 months. Secondary end-points were the change in BMD at the femoral neck and changes in biochemical markers of bone turnover. Results Forty-five women were recruited to participate in the study. Five subjects withdrew from the study before randomization for unrelated reasons. Forty subjects were randomly allocated to the alendronate and placebo groups. The mean lumbar spine BMD in women treated with alendronate increased by 3.66% (mean paired difference, d ¯ = 0.032 ; ± 0.008 S E ) at 12 months, compared with a reduction of 3.33% d ¯ = − 0.030 ; ± 0.008 S E in the control group ( P < 0.001). In the femoral neck, the mean BMD in the alendronate group increased by 2.07% d ¯ = 0.014 ; ± 0.009 S E at 12 months, compared with a reduction of 1.87% d ¯ = − 0.014 ; ± 0.008 S E in the control group ( P = 0.046). There were no differences in BMD between the alendronate and placebo groups at the total hip sites after 12 months. At 12 months, both bone-specific alkaline phosphatase and urinary N-telopeptide were significantly reduced, by 37.79% d ¯ = − 9.90 ; ± 1.92 S E and 27.21% d ¯ = − 11.68 ; ± 4.80 S E respectively, in the alendronate group; in the control group, these levels increased ( P < 0.001). Conclusion Weekly treatment with alendronate 70 mg and cholecalciferol 2800 IU increases BMD and decreases bone turnover in perimenopausal women. |
| doi_str_mv | 10.1016/S1701-2163(15)30410-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1645780502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1701216315304102</els_id><sourcerecordid>1645780502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-a0ff87810c93be6c3d52b21aedf09e88a1daf93a6aa75b44ab666f4901b392483</originalsourceid><addsrcrecordid>eNqFUctuFDEQnAOIhMAngHwMEgO2ZzyPC2izWR7SIqIElKPlsdvEwWtvbE_Q8nF8G56dkANC4mS1u7qqu6oonhH8imDSvL4gLSYlJU11TNiLCtcEl_RBcXj_fVA8jvEaY9ZWbf-oOKCMtXXT1ofFrwU6F075jfkJ6iU69eNgoTyxxuXqzAoJgy-X3qXgrQWFLtKodih5tLoVdhQJULoCtNIaZIrIa7Sw4FTwbmp5h068A_TJOAjColNw0aQdyoJz4xw2XoHNat-QcegMgtmA81sxxgy_9LlAlyZdobX_8U-qJ8VDLWyEp3fvUfH13erL8kO5_vz-43KxLmVNcSoF1rprO4JlXw3QyEoxOlAiQGncQ9cJooTuK9EI0bKhrsXQNI2ue0yGqqd1Vx0VxzPvNvibEWLiGxNl3lw48GPkpKlZ22GGaYayGSqDjzGA5tt8lQg7TjCf4uL7uPiUCyeM7-Pi09zzO4lx2IC6n_qTVQa8nQGQD701EHiUBpwEZUJ2nytv_ivx5i8Gma03UtjvsIN47cfgsouc8Eg5nkkmDsL2DLT6DU6evZU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645780502</pqid></control><display><type>article</type><title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Khan, Aliya, MD, FRCPC, FACP, FACE ; Dubois, Sacha, MPH ; Khan, Amina A ; Zohair Rahman, M., BSc ; Ahmed Khan, O., MD ; Syed, Hamid T ; Derzko, Christine, MD, FRCSC</creator><creatorcontrib>Khan, Aliya, MD, FRCPC, FACP, FACE ; Dubois, Sacha, MPH ; Khan, Amina A ; Zohair Rahman, M., BSc ; Ahmed Khan, O., MD ; Syed, Hamid T ; Derzko, Christine, MD, FRCSC</creatorcontrib><description>Abstract Background Perimenopausal women can experience rapid bone loss at skeletal sites with both cortical and cancellous bone, increasing the prevalence of osteoporosis following menopause. Methods We conducted a 12-month randomized placebo-controlled trial evaluating the effects of alendronate 70 mg with 2800 IU cholecalciferol administered once per week for 12 months in comparison with placebo and cholecalciferol. The primary end-point was the percentage change in the lumbar spine bone mineral density (BMD) from baseline to 12 months. Secondary end-points were the change in BMD at the femoral neck and changes in biochemical markers of bone turnover. Results Forty-five women were recruited to participate in the study. Five subjects withdrew from the study before randomization for unrelated reasons. Forty subjects were randomly allocated to the alendronate and placebo groups. The mean lumbar spine BMD in women treated with alendronate increased by 3.66% (mean paired difference, d ¯ = 0.032 ; ± 0.008 S E ) at 12 months, compared with a reduction of 3.33% d ¯ = − 0.030 ; ± 0.008 S E in the control group ( P < 0.001). In the femoral neck, the mean BMD in the alendronate group increased by 2.07% d ¯ = 0.014 ; ± 0.009 S E at 12 months, compared with a reduction of 1.87% d ¯ = − 0.014 ; ± 0.008 S E in the control group ( P = 0.046). There were no differences in BMD between the alendronate and placebo groups at the total hip sites after 12 months. At 12 months, both bone-specific alkaline phosphatase and urinary N-telopeptide were significantly reduced, by 37.79% d ¯ = − 9.90 ; ± 1.92 S E and 27.21% d ¯ = − 11.68 ; ± 4.80 S E respectively, in the alendronate group; in the control group, these levels increased ( P < 0.001). Conclusion Weekly treatment with alendronate 70 mg and cholecalciferol 2800 IU increases BMD and decreases bone turnover in perimenopausal women.</description><identifier>ISSN: 1701-2163</identifier><identifier>DOI: 10.1016/S1701-2163(15)30410-2</identifier><identifier>PMID: 25574674</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Adult ; alendronate ; Alendronate - therapeutic use ; bisphosphonate ; Bone Density Conservation Agents - therapeutic use ; Bone Remodeling - drug effects ; Cholecalciferol - therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; fracture risk ; Humans ; Middle Aged ; Obstetrics and Gynecology ; osteoporosis ; Osteoporosis - drug therapy ; Perimenopause</subject><ispartof>Journal of obstetrics and gynaecology Canada, 2014-11, Vol.36 (11), p.976-982</ispartof><rights>Society of Obstetricians and Gynaecologists of Canada</rights><rights>2014 Society of Obstetricians and Gynaecologists of Canada</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-a0ff87810c93be6c3d52b21aedf09e88a1daf93a6aa75b44ab666f4901b392483</citedby><cites>FETCH-LOGICAL-c420t-a0ff87810c93be6c3d52b21aedf09e88a1daf93a6aa75b44ab666f4901b392483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25574674$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khan, Aliya, MD, FRCPC, FACP, FACE</creatorcontrib><creatorcontrib>Dubois, Sacha, MPH</creatorcontrib><creatorcontrib>Khan, Amina A</creatorcontrib><creatorcontrib>Zohair Rahman, M., BSc</creatorcontrib><creatorcontrib>Ahmed Khan, O., MD</creatorcontrib><creatorcontrib>Syed, Hamid T</creatorcontrib><creatorcontrib>Derzko, Christine, MD, FRCSC</creatorcontrib><title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density</title><title>Journal of obstetrics and gynaecology Canada</title><addtitle>J Obstet Gynaecol Can</addtitle><description>Abstract Background Perimenopausal women can experience rapid bone loss at skeletal sites with both cortical and cancellous bone, increasing the prevalence of osteoporosis following menopause. Methods We conducted a 12-month randomized placebo-controlled trial evaluating the effects of alendronate 70 mg with 2800 IU cholecalciferol administered once per week for 12 months in comparison with placebo and cholecalciferol. The primary end-point was the percentage change in the lumbar spine bone mineral density (BMD) from baseline to 12 months. Secondary end-points were the change in BMD at the femoral neck and changes in biochemical markers of bone turnover. Results Forty-five women were recruited to participate in the study. Five subjects withdrew from the study before randomization for unrelated reasons. Forty subjects were randomly allocated to the alendronate and placebo groups. The mean lumbar spine BMD in women treated with alendronate increased by 3.66% (mean paired difference, d ¯ = 0.032 ; ± 0.008 S E ) at 12 months, compared with a reduction of 3.33% d ¯ = − 0.030 ; ± 0.008 S E in the control group ( P < 0.001). In the femoral neck, the mean BMD in the alendronate group increased by 2.07% d ¯ = 0.014 ; ± 0.009 S E at 12 months, compared with a reduction of 1.87% d ¯ = − 0.014 ; ± 0.008 S E in the control group ( P = 0.046). There were no differences in BMD between the alendronate and placebo groups at the total hip sites after 12 months. At 12 months, both bone-specific alkaline phosphatase and urinary N-telopeptide were significantly reduced, by 37.79% d ¯ = − 9.90 ; ± 1.92 S E and 27.21% d ¯ = − 11.68 ; ± 4.80 S E respectively, in the alendronate group; in the control group, these levels increased ( P < 0.001). Conclusion Weekly treatment with alendronate 70 mg and cholecalciferol 2800 IU increases BMD and decreases bone turnover in perimenopausal women.</description><subject>Adult</subject><subject>alendronate</subject><subject>Alendronate - therapeutic use</subject><subject>bisphosphonate</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone Remodeling - drug effects</subject><subject>Cholecalciferol - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>fracture risk</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Obstetrics and Gynecology</subject><subject>osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Perimenopause</subject><issn>1701-2163</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUctuFDEQnAOIhMAngHwMEgO2ZzyPC2izWR7SIqIElKPlsdvEwWtvbE_Q8nF8G56dkANC4mS1u7qqu6oonhH8imDSvL4gLSYlJU11TNiLCtcEl_RBcXj_fVA8jvEaY9ZWbf-oOKCMtXXT1ofFrwU6F075jfkJ6iU69eNgoTyxxuXqzAoJgy-X3qXgrQWFLtKodih5tLoVdhQJULoCtNIaZIrIa7Sw4FTwbmp5h068A_TJOAjColNw0aQdyoJz4xw2XoHNat-QcegMgtmA81sxxgy_9LlAlyZdobX_8U-qJ8VDLWyEp3fvUfH13erL8kO5_vz-43KxLmVNcSoF1rprO4JlXw3QyEoxOlAiQGncQ9cJooTuK9EI0bKhrsXQNI2ue0yGqqd1Vx0VxzPvNvibEWLiGxNl3lw48GPkpKlZ22GGaYayGSqDjzGA5tt8lQg7TjCf4uL7uPiUCyeM7-Pi09zzO4lx2IC6n_qTVQa8nQGQD701EHiUBpwEZUJ2nytv_ivx5i8Gma03UtjvsIN47cfgsouc8Eg5nkkmDsL2DLT6DU6evZU</recordid><startdate>20141101</startdate><enddate>20141101</enddate><creator>Khan, Aliya, MD, FRCPC, FACP, FACE</creator><creator>Dubois, Sacha, MPH</creator><creator>Khan, Amina A</creator><creator>Zohair Rahman, M., BSc</creator><creator>Ahmed Khan, O., MD</creator><creator>Syed, Hamid T</creator><creator>Derzko, Christine, MD, FRCSC</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20141101</creationdate><title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density</title><author>Khan, Aliya, MD, FRCPC, FACP, FACE ; Dubois, Sacha, MPH ; Khan, Amina A ; Zohair Rahman, M., BSc ; Ahmed Khan, O., MD ; Syed, Hamid T ; Derzko, Christine, MD, FRCSC</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-a0ff87810c93be6c3d52b21aedf09e88a1daf93a6aa75b44ab666f4901b392483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>alendronate</topic><topic>Alendronate - therapeutic use</topic><topic>bisphosphonate</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone Remodeling - drug effects</topic><topic>Cholecalciferol - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>fracture risk</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Obstetrics and Gynecology</topic><topic>osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Perimenopause</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khan, Aliya, MD, FRCPC, FACP, FACE</creatorcontrib><creatorcontrib>Dubois, Sacha, MPH</creatorcontrib><creatorcontrib>Khan, Amina A</creatorcontrib><creatorcontrib>Zohair Rahman, M., BSc</creatorcontrib><creatorcontrib>Ahmed Khan, O., MD</creatorcontrib><creatorcontrib>Syed, Hamid T</creatorcontrib><creatorcontrib>Derzko, Christine, MD, FRCSC</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of obstetrics and gynaecology Canada</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khan, Aliya, MD, FRCPC, FACP, FACE</au><au>Dubois, Sacha, MPH</au><au>Khan, Amina A</au><au>Zohair Rahman, M., BSc</au><au>Ahmed Khan, O., MD</au><au>Syed, Hamid T</au><au>Derzko, Christine, MD, FRCSC</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density</atitle><jtitle>Journal of obstetrics and gynaecology Canada</jtitle><addtitle>J Obstet Gynaecol Can</addtitle><date>2014-11-01</date><risdate>2014</risdate><volume>36</volume><issue>11</issue><spage>976</spage><epage>982</epage><pages>976-982</pages><issn>1701-2163</issn><abstract>Abstract Background Perimenopausal women can experience rapid bone loss at skeletal sites with both cortical and cancellous bone, increasing the prevalence of osteoporosis following menopause. Methods We conducted a 12-month randomized placebo-controlled trial evaluating the effects of alendronate 70 mg with 2800 IU cholecalciferol administered once per week for 12 months in comparison with placebo and cholecalciferol. The primary end-point was the percentage change in the lumbar spine bone mineral density (BMD) from baseline to 12 months. Secondary end-points were the change in BMD at the femoral neck and changes in biochemical markers of bone turnover. Results Forty-five women were recruited to participate in the study. Five subjects withdrew from the study before randomization for unrelated reasons. Forty subjects were randomly allocated to the alendronate and placebo groups. The mean lumbar spine BMD in women treated with alendronate increased by 3.66% (mean paired difference, d ¯ = 0.032 ; ± 0.008 S E ) at 12 months, compared with a reduction of 3.33% d ¯ = − 0.030 ; ± 0.008 S E in the control group ( P < 0.001). In the femoral neck, the mean BMD in the alendronate group increased by 2.07% d ¯ = 0.014 ; ± 0.009 S E at 12 months, compared with a reduction of 1.87% d ¯ = − 0.014 ; ± 0.008 S E in the control group ( P = 0.046). There were no differences in BMD between the alendronate and placebo groups at the total hip sites after 12 months. At 12 months, both bone-specific alkaline phosphatase and urinary N-telopeptide were significantly reduced, by 37.79% d ¯ = − 9.90 ; ± 1.92 S E and 27.21% d ¯ = − 11.68 ; ± 4.80 S E respectively, in the alendronate group; in the control group, these levels increased ( P < 0.001). Conclusion Weekly treatment with alendronate 70 mg and cholecalciferol 2800 IU increases BMD and decreases bone turnover in perimenopausal women.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>25574674</pmid><doi>10.1016/S1701-2163(15)30410-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1701-2163 |
| ispartof | Journal of obstetrics and gynaecology Canada, 2014-11, Vol.36 (11), p.976-982 |
| issn | 1701-2163 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1645780502 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult alendronate Alendronate - therapeutic use bisphosphonate Bone Density Conservation Agents - therapeutic use Bone Remodeling - drug effects Cholecalciferol - therapeutic use Double-Blind Method Drug Therapy, Combination Female fracture risk Humans Middle Aged Obstetrics and Gynecology osteoporosis Osteoporosis - drug therapy Perimenopause |
| title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Alendronate on Bone Mineral Density and Bone Remodelling in Perimenopausal Women With Low Bone Mineral Density |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A58%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Randomized,%20Double-Blind,%20Placebo-Controlled%20Study%20to%20Evaluate%20the%20Effects%20of%20Alendronate%20on%20Bone%20Mineral%20Density%20and%20Bone%20Remodelling%20in%20Perimenopausal%20Women%20With%20Low%20Bone%20Mineral%20Density&rft.jtitle=Journal%20of%20obstetrics%20and%20gynaecology%20Canada&rft.au=Khan,%20Aliya,%20MD,%20FRCPC,%20FACP,%20FACE&rft.date=2014-11-01&rft.volume=36&rft.issue=11&rft.spage=976&rft.epage=982&rft.pages=976-982&rft.issn=1701-2163&rft_id=info:doi/10.1016/S1701-2163(15)30410-2&rft_dat=%3Cproquest_cross%3E1645780502%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645780502&rft_id=info:pmid/25574674&rft_els_id=S1701216315304102&rfr_iscdi=true |